Institutional Fund
Kynam Capital Management, LP
Princeton, NJCIK 19078845 filings on record
Portfolio Value
$1.58B
Q1 2026
Holdings
36
Reported positions
New Buys
4
Opened this quarter
QoQ Change
+2.6%
from $1.54B
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Syndax Pharmaceuticals Inc11.9%
- Celldex Therapeutics Inc New11.8%
- Vaxcyte Inc10.8%
- Cogent Biosciences Inc9.9%
- Vera Therapeutics Inc8.7%
- Beam Therapeutics Inc5.6%
- Other41.4%
Portfolio Holdings
36 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Syndax Pharmaceuticals Inc | 8.05M | $188.07M | 11.9% | 0 | Held |
| 2 | Celldex Therapeutics Inc New | 5.84M | $185.26M | 11.8% | −102.6K | Reduced |
| 3 | Vaxcyte Inc | 2.92M | $169.82M | 10.8% | 0 | Held |
| 4 | Cogent Biosciences Inc | 4.04M | $155.40M | 9.9% | −2.13M | Reduced |
| 5 | Vera Therapeutics Inc | 3.40M | $136.71M | 8.7% | −34.8K | Reduced |
| 6 | Beam Therapeutics Inc | 3.68M | $87.75M | 5.6% | +1.24M | Added |
| 7 | Cytomx Therapeutics Inc | 15.01M | $70.56M | 4.5% | +6.05M | Added |
| 8 | Biocryst Pharmaceuticals Inc | 5.68M | $54.08M | 3.4% | −3.69M | Reduced |
| 9 | Travere Therapeutics Inc | 1.57M | $46.62M | 3.0% | +1.05M | Added |
| 10 | Viridian Therapeutics Inc | 2.34M | $45.80M | 2.9% | +871.1K | Added |
26 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio